Literature DB >> 31233196

Downregulation of PDCD4 induced by progesterone is mediated by the PI3K/AKT signaling pathway in human endometrial cancer cells.

Xishuang Wang1, Yue Li1, Lu Wan1, Yanping Liu2, Yingshuo Sun2, Yuqiu Liu2, Yongyu Shi1, Lining Zhang1, Huaiyu Zhou3, Jianing Wang1, Xiaoyan Wang1, Zengtao Wei1.   

Abstract

Programmed cell death 4 (PDCD4) has been identified as a tumor‑suppressor gene that inhibits neoplastic transformation, tumor progression, and protein translation. It has been reported that multiple factors participate in the regulation of PDCD4 mRNA and protein. The endometrium is regulated by changing concentrations of ovarian hormones, such as estrogen and progesterone, and shows periodical changes. However, whether ovarian hormones regulate PDCD4 expression remains unclear. This study aimed to explore the effect and mechanism of estrogen or progesterone on PDCD4 mRNA and protein expression in human endometrial cancer cells. The expression of PDCD4 mRNA and protein in Ishikawa and HEC‑1‑A cells was detected by quantitative real‑time PCR and western blot analysis. The signaling pathway‑related proteins were detected by western blot analysis. The results showed that PDCD4 mRNA levels exhibited no significant changes after treatment with estrogen or progesterone in both Ishikawa and HEC‑1‑A cell lines. Estrogen also had no obvious effect on PDCD4 protein expression. However, progesterone effectively decreased the expression of PDCD4 protein and the PI3K/AKT pathway may be involved in the downregulation of PDCD4 protein induced by progesterone. These results suggest that the downregulation of PDCD4 induced by progesterone affects the therapeutic efficacy of progesterone in human endometrial cancer or endometriosis, which may have important implications for progesterone treatment in the clinic.

Entities:  

Year:  2019        PMID: 31233196     DOI: 10.3892/or.2019.7202

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  Ovarian hormones-autophagy-immunity axis in menstruation and endometriosis.

Authors:  Hui-Hui Shen; Tao Zhang; Hui-Li Yang; Zhen-Zhen Lai; Wen-Jie Zhou; Jie Mei; Jia-Wei Shi; Rui Zhu; Feng-Yuan Xu; Da-Jin Li; Jiang-Feng Ye; Ming-Qing Li
Journal:  Theranostics       Date:  2021-01-19       Impact factor: 11.556

2.  Role of programmed cell death 4 in myofibroblast differentiation in oral submucous fibrosis.

Authors:  Karishma Madhusudan Desai; Alka Dinesh Kale; Punnya V Angadi; Uma V Datar; Chetan Belaldavar; Praveen R Arany
Journal:  J Oral Maxillofac Pathol       Date:  2022-01-11

3.  AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B.

Authors:  Jia Xu; Xufen Yu; Tiphaine C Martin; Ankita Bansal; Kakit Cheung; Abigail Lubin; Elias Stratikopoulos; Kaitlyn M Cahuzac; Li Wang; Ling Xie; Royce Zhou; Yudao Shen; Xuewei Wu; Shen Yao; Ruifang Qiao; Poulikos I Poulikakos; Xian Chen; Jing Liu; Jian Jin; Ramon Parsons
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

4.  Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer.

Authors:  Xiao Huo; Hengzi Sun; Qian Liu; Xiangwen Ma; Peng Peng; Mei Yu; Ying Zhang; Dongyan Cao; Keng Shen
Journal:  Front Oncol       Date:  2019-11-06       Impact factor: 6.244

Review 5.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

6.  Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor.

Authors:  Marya Kozinova; Shalina Joshi; Shuai Ye; Martin G Belinsky; Dinara Sharipova; Jeffrey M Farma; Sanjay S Reddy; Samuel Litwin; Karthik Devarajan; Alex Rosa Campos; Yi Yu; Brian Schwartz; Margaret von Mehren; Lori Rink
Journal:  Cancers (Basel)       Date:  2021-07-23       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.